1932

Abstract

Hereditary diffuse gastric cancer (HDGC) is a cancer syndrome associated with a significant lifetime risk of diffuse gastric cancer (DGC), a malignancy characterized by late clinical presentation and poor prognosis, as well as lobular breast cancer. HDGC is linked to germline pathogenic variants in the E-cadherin gene () that are inherited in an autosomal dominant pattern; however, in many families with DGC clustering, no genetic cause has been identified. This review discusses key elements that allow risk assessment of potential inherited DGC susceptibility. We provide a practical overview of the recommendations for surveillance and treatment of individuals at risk and patients with early disease. The review also outlines future research avenues to improve our understanding of the genetic background and natural history of the disease, the endoscopic detection of early lesions, and the outcome of prophylactic surgery in young individuals.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-051019-103216
2021-01-27
2024-06-16
Loading full text...

Full text loading...

/deliver/fulltext/med/72/1/annurev-med-051019-103216.html?itemId=/content/journals/10.1146/annurev-med-051019-103216&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Jones EG. 1964. Familial gastric cancer. N. Z. Med. J. 63:287–96
    [Google Scholar]
  2. 2. 
    Guilford P, Hopkins J, Harraway J et al. 1998. E-cadherin germline mutations in familial gastric cancer. Nature 392:6674402–5
    [Google Scholar]
  3. 3. 
    Caldas C, Carneiro F, Lynch HT et al. 1999. Familial gastric cancer: overview and guidelines for management. J. Med. Genet. 36:12873–80
    [Google Scholar]
  4. 4. 
    Lecuit T, Yap AS. 2015. E-cadherin junctions as active mechanical integrators in tissue dynamics. Nat. Cell Biol. 17:5533–39
    [Google Scholar]
  5. 5. 
    Hansford S, Kaurah P, Li-Chang H et al. 2015. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol 1:23–32
    [Google Scholar]
  6. 6. 
    Majewski IJ, Kluijt I, Cats A et al. 2013. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J. Pathol. 229:4621–29
    [Google Scholar]
  7. 7. 
    Benusiglio PR, Colas C, Guillerm E et al. 2019. Clinical implications of CTNNA1 germline mutations in asymptomatic carriers. Gastric Cancer 22:4899–903
    [Google Scholar]
  8. 8. 
    Gaston D, Hansford S, Oliveira C et al. 2014. Germline mutations in MAP3K6 are associated with familial gastric cancer. PLOS Genet 10:10e1004669
    [Google Scholar]
  9. 9. 
    Fewings E, Larionov A, Redman J et al. 2018. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Lancet Gastroenterol. Hepatol. 3:7489–98
    [Google Scholar]
  10. 10. 
    Xicola RM, Li S, Rodriguez N et al. 2019. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J. Med. Genet. 56:12838–43
    [Google Scholar]
  11. 11. 
    van der Post RS, Vogelaar IP, Carneiro F et al. 2015. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J. Med. Genet. 52:6361–74
    [Google Scholar]
  12. 12. 
    Roberts ME, Ranola JMO, Marshall ML et al. 2019. Comparison of CDH1 penetrance estimates in clinically ascertained families versus families ascertained for multiple gastric cancers. JAMA Oncol 5:91325–31
    [Google Scholar]
  13. 13. 
    Guilford P. 2020. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 21:8e386–e397
    [Google Scholar]
  14. 14. 
    van der Kaaij RT, Koemans WJ, van Putten M et al. 2020. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015. Eur. J. Cancer 130:23–31
    [Google Scholar]
  15. 15. 
    Stone J, Bevan S, Cunningham D et al. 1999. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br. J. Cancer 79:11–121935–37
    [Google Scholar]
  16. 16. 
    Mi EZ, Mi EZ, di Pietro M et al. 2018. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointest. Endosc. 87:2408–18
    [Google Scholar]
  17. 17. 
    van der Post RS, Vogelaar IP, Manders P et al. 2015. Accuracy of hereditary diffuse gastric cancer testing criteria and outcomes in patients with a germline mutation in CDH1. . Gastroenterology 149:4897–906.e19
    [Google Scholar]
  18. 18. 
    Lu KH, Wood ME, Daniels M et al. 2014. American Society of Clinical Oncology expert statement: collection and use of a cancer family history for oncology providers. J. Clin. Oncol. 32:8833–40
    [Google Scholar]
  19. 19. 
    Brooks-Wilson AR, Kaurah P, Suriano G et al. 2004. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J. Med. Genet. 41:7508–17
    [Google Scholar]
  20. 20. 
    Kaurah P, MacMillan A, Boyd N et al. 2007. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297:212360–72
    [Google Scholar]
  21. 21. 
    Petridis C, Arora I, Shah V et al. 2019. Frequency of pathogenic germline variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in sporadic lobular breast cancer. Cancer Epidemiol. Biomarkers Prev 28:71162–68
    [Google Scholar]
  22. 22. 
    Clark DF, Michalski ST, Tondon R et al. 2020. Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. Genet. Med. 22:5840–46
    [Google Scholar]
  23. 23. 
    Richards S, Aziz N, Bale S et al. 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17:5405–24
    [Google Scholar]
  24. 24. 
    Lee K, Krempely K, Roberts ME et al. 2018. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants. Hum. Mutat. 39:111553–68
    [Google Scholar]
  25. 25. 
    Vogelaar IP, van der Post RS, van Krieken JHJM et al. 2017. Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. Eur. J. Hum. Genet. 25:111246–52
    [Google Scholar]
  26. 26. 
    Sahasrabudhe R, Lott P, Bohorquez M et al. 2017. Germline mutations in PALB2, BRCA1, and RAD51C, which regulate DNA recombination repair, in patients with gastric cancer. Gastroenterology 152:5983–86.e6
    [Google Scholar]
  27. 27. 
    Rocha JP, Gullo I, Wen X et al. 2018. Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. Histopathology 73:6878–86
    [Google Scholar]
  28. 28. 
    Pharoah PD, Guilford P, Caldas C 2001. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121:61348–53
    [Google Scholar]
  29. 29. 
    Han MA, Oh MG, Choi J et al. 2012. Association of family history with cancer recurrence and survival in patients with gastric cancer. J. Clin. Oncol. 30:7701–8
    [Google Scholar]
  30. 30. 
    van der Post RS, Gullo I, Oliveira C et al. 2016. Histopathological, molecular, and genetic profile of hereditary diffuse gastric cancer: current knowledge and challenges for the future. Adv. Exp. Med. Biol. 908:371–91
    [Google Scholar]
  31. 31. 
    Jacobs MF, Dust H, Koeppe E et al. 2019. Outcomes of endoscopic surveillance in individuals with genetic predisposition to hereditary diffuse gastric cancer. Gastroenterology 157:187–96
    [Google Scholar]
  32. 32. 
    van Dieren JM, Kodach LL, den Hartog P et al. 2020. Gastroscopic surveillance with targeted biopsies compared with random biopsies in CDH1 mutation carriers. Endoscopy 52:10839–46
    [Google Scholar]
  33. 33. 
    Carneiro F, Huntsman DG, Smyrk TC et al. 2004. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J. Pathol. 203:2681–87
    [Google Scholar]
  34. 34. 
    Carneiro F, Fukayama M, Grabsch HI et al. 2019. Hereditary diffuse gastric cancer. WHO Classification of Tumours: Digestive System Tumours WHO Classification of Tumors Editorial Board 84 Lyon: Int. Agency Res. Cancer
    [Google Scholar]
  35. 35. 
    Oliveira C, Pinheiro H, Figueiredo J et al. 2015. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 16:2e60–70
    [Google Scholar]
  36. 36. 
    Charlton A, Blair V, Shaw D et al. 2004. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53:6814–20
    [Google Scholar]
  37. 37. 
    Keller G, Vogelsang H, Becker I et al. 1999. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am. J. Pathol. 155:2337–42
    [Google Scholar]
  38. 38. 
    Benusiglio PR, Malka D, Rouleau E et al. 2013. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J. Med. Genet. 50:7486–89
    [Google Scholar]
  39. 39. 
    Petridis C, Shinomiya I, Kohut K et al. 2014. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br. J. Cancer 110:41053–57
    [Google Scholar]
  40. 40. 
    Ciriello G, Gatza ML, Beck AH et al. 2015. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:2506–19
    [Google Scholar]
  41. 41. 
    Corso G, Figueiredo J, La Vecchia C et al. 2018. Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. J. Med. Genet. 55:7431–41
    [Google Scholar]
  42. 42. 
    Corso G, Intra M, Trentin C et al. 2016. CDH1 germline mutations and hereditary lobular breast cancer. Fam. Cancer 15:2215–19
    [Google Scholar]
  43. 43. 
    Richards FM, McKee SA, Rajpar MH et al. 1999. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum. Mol. Genet. 8:4607–10
    [Google Scholar]
  44. 44. 
    Kim H, Wheeler J, Kim J et al. 2000. The E-cadherin gene (CDH1) variants T340A and L599V in gastric and colorectal cancer patients in Korea. Gut 47:2262–67
    [Google Scholar]
  45. 45. 
    Frebourg T, Oliveira C, Hochain P et al. 2006. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. J. Med. Genet. 43:2138–42
    [Google Scholar]
  46. 46. 
    Obermair F, Rammer M, Burghofer J et al. 2019. Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687+1G>A germline mutation and review of the literature. Fam. Cancer 18:2253–60
    [Google Scholar]
  47. 47. 
    Dixon MJ, Marazita ML, Beaty TH, Murray JC 2011. Cleft lip and palate: understanding genetic and environmental influences. Nat. Rev. Genet. 12:3167–78
    [Google Scholar]
  48. 48. 
    Hüneburg R, Marwitz T, van Heteren P et al. 2016. Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients. Endosc. Int. Open 4:12E1305–10
    [Google Scholar]
  49. 49. 
    Shaw D, Blair V, Framp A et al. 2005. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy. Gut 54:4461–68
    [Google Scholar]
  50. 50. 
    Humar B, Fukuzawa R, Blair V et al. 2007. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 67:62480–89
    [Google Scholar]
  51. 51. 
    Pappas A, Waldock W, Tripathi M et al. 2020. Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-centre, randomized trial. Endoscopy https://doi.org/10.1055/a-1201-3125
    [Crossref] [Google Scholar]
  52. 52. 
    Gullo I, Devezas V, Baptista M et al. 2018. Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease. Gastrointest. Endosc. 87:61566–75
    [Google Scholar]
  53. 53. 
    Sugimoto S, Komatsu H, Morohoshi Y et al. 2015. Recognition of and recent issues in hereditary diffuse gastric cancer. J. Gastroenterol. 50:8831–43
    [Google Scholar]
  54. 54. 
    Pinheiro H, Oliveira C, Seruca R, Carneiro F 2014. Hereditary diffuse gastric cancer—pathophysiology and clinical management. Best Pract. Res. Clin. Gastroenterol. 28:61055–68
    [Google Scholar]
  55. 55. 
    Brem RF, Ioffe M, Rapelyea JA et al. 2009. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am. J. Roentgenol. 192:2379–83
    [Google Scholar]
  56. 56. 
    Weber WP, Haug M, Kurzeder C et al. 2018. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. Breast Cancer Res. Treat. 172:3523–37
    [Google Scholar]
  57. 57. 
    Le Gal M, Ollivier L, Asselain B et al. 1992. Mammographic features of 455 invasive lobular carcinomas. Radiology 185:3705–8
    [Google Scholar]
  58. 58. 
    EviQ 2020. CDH1—risk management ID 1090 v.7, EviQ, Sydney https://www.eviq.org.au/cancer-genetics/adult/risk-management/1090-cdh1-risk-management
    [Google Scholar]
  59. 59. 
    NICE (Natl. Inst. Health and Care Excellence) 2019. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical Guideline CG164, Natl. Inst. Health and Care Excellence, London https://www.nice.org.uk/guidance/cg164/ifp/chapter/familial-breast-cancer
    [Google Scholar]
  60. 60. 
    Paluch-Shimon S, Sessa C, Cardoso MJ et al. 2016. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 27:Suppl. 5v103–v110
    [Google Scholar]
  61. 61. 
    NCCN (Natl. Compr. Cancer Netw.) 2019. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian and pancreatic. NCCN Guideline, version 1.2020, Natl. Compr. Cancer Netw., Plymouth Meeting, PA https://www.nccn.org/professionals/physician_gls/#detection
    [Google Scholar]
  62. 62. 
    Ha SM, Chae EY, Cha JH et al. 2018. Breast MR imaging before surgery: outcomes in patients with invasive lobular carcinoma by using propensity score matching. Radiology 287:3771–77
    [Google Scholar]
  63. 63. 
    Selinko VL, Middleton LP, Dempsey PJ 2004. Role of sonography in diagnosing and staging invasive lobular carcinoma. J. Clin. Ultrasound 32:7323–32
    [Google Scholar]
  64. 64. 
    Strong VE, Gholami S, Shah M et al. 2017. Total gastrectomy for hereditary diffuse gastric cancer at a single center: postsurgical outcomes in 41 patients. Ann. Surg. 266:61006–12
    [Google Scholar]
  65. 65. 
    Haverkamp L, van der Sluis PC, Ausems MGEM et al. 2015. Prophylactic laparoscopic total gastrectomy with jejunal pouch reconstruction in patients carrying a CDH1 germline mutation. J. Gastrointest. Surg. 19:122120–25
    [Google Scholar]
  66. 66. 
    Hebbard PC, Macmillan A, Huntsman D et al. 2009. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann. Surg. Oncol. 16:71890–95
    [Google Scholar]
  67. 67. 
    van der Kaaij RT, van Kessel JP, van Dieren JM et al. 2018. Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer. Br. J. Surg. 105:2e176–e182
    [Google Scholar]
  68. 68. 
    Newman EA, Mulholland MW. 2006. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J. Am. Coll. Surg. 202:4612–17
    [Google Scholar]
  69. 69. 
    Liedman B, Andersson H, Bosaeus I et al. 1997. Changes in body composition after gastrectomy: results of a controlled, prospective clinical trial. World J. Surg. 21:4416–20
    [Google Scholar]
  70. 70. 
    Lewis FR, Mellinger JD, Hayashi A et al. 2001. Prophylactic total gastrectomy for familial gastric cancer. Surgery 130:4612–17
    [Google Scholar]
  71. 71. 
    Schmidt B, Yoon SS. 2013. D1 versus D2 lymphadenectomy for gastric cancer. J. Surg. Oncol. 107:3259–64
    [Google Scholar]
  72. 72. 
    Pantelis D, Hüneburg R, Adam R et al. 2016. Prophylactic total gastrectomy in the management of hereditary tumor syndromes. Int. J. Colorectal Dis. 31:121825–33
    [Google Scholar]
  73. 73. 
    Hackenson D, Edelman DA, McGuire T et al. 2010. Prophylactic laparoscopic gastrectomy for hereditary diffuse gastric cancer: a case series in a single family. JSLS 14:3348–52
    [Google Scholar]
  74. 74. 
    Hallowell N, Lawton J, Badger S et al. 2017. The psychosocial impact of undergoing prophylactic total gastrectomy (PTG) to manage the risk of hereditary diffuse gastric cancer (HDGC). J. Genet. Couns. 26:4752–62
    [Google Scholar]
  75. 75. 
    Muir J, Aronson M, Esplen M et al. 2016. Prophylactic total gastrectomy: a prospective cohort study of long-term impact on quality of life. J. Gastrointest. Surg. 20:121950–58
    [Google Scholar]
  76. 76. 
    Jakub JW, Peled AW, Gray RJ et al. 2018. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg 153:2123–29
    [Google Scholar]
  77. 77. 
    Luveta J, Parks RM, Heery DM et al. 2019. Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy. Oncol. Ther. 8:1–11
    [Google Scholar]
  78. 78. 
    Johnson SJ, Cheung K-L. 2018. Endocrine therapy for breast cancer: a model of hormonal manipulation. Oncol. Ther. 6:2141–56
    [Google Scholar]
  79. 79. 
    Kar SP, Beesley J, Al Olama AA et al. 2016. Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. Cancer Discov 6:91052–67
    [Google Scholar]
  80. 80. 
    Tsai TH, Leggett CL, Trindade AJ et al. 2017. Optical coherence tomography in gastroenterology: a review and future outlook. J. Biomed. Opt. 22:12121716
    [Google Scholar]
  81. 81. 
    Mann NS, Mann SK, Rachut E 2000. Heterotopic gastric tissue in the duodenal bulb. J. Clin. Gastroenterol. 30:3303–6
    [Google Scholar]
  82. 82. 
    Hansen CC, Søreide K. 2018. Systematic review of epidemiology, presentation, and management of Meckel's diverticulum in the 21st century. Medicine 97:35e12154
    [Google Scholar]
  83. 83. 
    Bridoux V, Kianifard B, Schwarz L et al. 2012. Hereditary diffuse gastric cancer: the always-forgotten Meckel's diverticulum. Surgery 151:2342
    [Google Scholar]
  84. 84. 
    Emous M, Ubels FL, van Beek AP 2015. Diagnostic tools for post-gastric bypass hypoglycaemia. Obes. Rev. 16:10843–56
    [Google Scholar]
  85. 85. 
    ten Kulve JS, Veltman DJ, Gerdes VEA et al. 2017. Elevated postoperative endogenous GLP-1 levels mediate effects of Roux-en-Y gastric bypass on neural responsivity to food cues. Diabetes Care 40:111522–29
    [Google Scholar]
  86. 86. 
    Svane MS, Bojsen-Møller KN, Nielsen S et al. 2016. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. Am. J. Physiol. Endocrinol. Metab. 310:7E505–14
    [Google Scholar]
/content/journals/10.1146/annurev-med-051019-103216
Loading
/content/journals/10.1146/annurev-med-051019-103216
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error